Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock

Avalo Therapeutics' Chief Medical Officer, Mittie Doyle, sold 1,000 shares of the company's common stock and exercised stock options on August 17, 2026, as reported in a recent SEC Form 4 filing. Doyle's sale was executed under a Rule 10b5-1 trading plan, which was established on November 13, 2025. The Chief Medical Officer sold her shares at $20.00 per share, resulting in a total of $20,000 from the sale.

Despite the stock's 83% return over the past year, InvestingPro analysts have indicated that the stock might be overvalued at its current price of $19.34, near its 52-week high of $24.27. Concurrent with her stock sale, Doyle acquired 1,000 shares of Avalo Therapeutics common stock by exercising stock options. The exercise price was $12.65 per share, totaling $12,650 for the acquisition.

This acquisition is part of a grant that vested 25% on July 15, 2025, with the remainder vesting in equal monthly installments over the next three years, contingent on Doyle's continued employment with the company. Following these transactions, Mittie Doyle now directly owns 51,776 shares of Avalo Therapeutics common stock, in addition to holding 123,750 derivative securities in the form of stock options.